WNT signaling: biomarker and target evaluation in Alzheimer’s disease

https://neurodegenerationresearch.eu/survey/wnt-signaling-biomarker-and-target-evaluation-in-alzheimers-disease/

Principal Investigators

Professor S Lovestone

Institution

University of Oxford

Contact information of lead PI
Country

United Kingdom

Title of project or programme

WNT signaling: biomarker and target evaluation in Alzheimer's disease

Source of funding information

MRC

Total sum awarded (Euro)

€ 298,443

Start date of award

06/05/2014

Total duration of award in years

2

Keywords
Research Abstract
The consistent failure of biopharmaceutical pipelines to modify Alzheimer’s disease progression indicates a need for new and creative solutions. In this project we will explore elements of the canonical (WNT/GSK3) and non-canonical (WNT/JNK) signaling pathways as novel targets that could be used to monitor and modify Alzheimer’s progression. Our teams are applying a multidisciplinary approach that combines brain-oriented drug screening, new genetic and pharmacological tools, new animal models and human blood and cerebrospinal fluid samples, which, together, explore the impact on AD of novel WNT elements, including but not limited to the apolipoprotein clusterin, the WNT inhibitor DKK1 and the transcription factor Nrf2.

Further information available at:

Types:
Investments < €500k

Member States:
United Kingdom

Diseases:
N/A

Years:
2016

Database Categories:
N/A

Database Tags:
N/A